RxDoctor Payments Data

William Stapleton, MD

Ophthalmology · Yakima, WANPI 1447462353

Payments from drug & device makers

$1,302in general payments, 2019–2025

Across 60 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$333
  • Alcon$209
  • Regeneron Healthcare Solutions, Inc.$109
  • Carl Zeiss Meditec USA, Inc.$96
  • AbbVie$96
  • Sun Pharmaceutical Industries Inc.$92
  • plus $367 from 10 others

What the payments were for

  • Food & beverage$1,28599%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,302 in reported general payments places this provider in the 55th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$442,942
Medicare patients
639
Services billed
3,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium59$20,850
Prednisolone Acetate406$13,175
RhopressaNetarsudil Mesylate17$5,216
Timolol Maleate146$4,953
Ofloxacin341$4,094
RocklatanNetarsudil Mesylat/Latanoprost11$3,443
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,418
Latanoprost325$3,223
Lotemax SmLoteprednol Etabonate12$3,056
CombiganBrimonidine Tartrate/Timolol13$2,447
Bromfenac Sodium13$1,982
ErythromycinErythromycin Base145$1,465
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat79$1,448
Brimonidine Tartrate60$1,236
Pilocarpine Hcl11$614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm$45$23,90671 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$73$8,65928 claims
AbbVieCombigan$96$2,44713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →